Nello Mainolfi

KYMR CEO Nello Mainolfi sells 80,000 shares for $9,223,527.48 via 5 separate transactions; 10b5-1 plan

Nello Mainolfi executed 5 separate sales totaling 80,000 shares (80.0K shares) for $9,223,527.48 ($9.2M) on 2026-07-01 under a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings from 746,568 shares to 666,568 shares (-10.7% vs pre-transaction). The insider retains 135,559 shares in stock options. Kymera is trading 12.7% below its 52-week high of $130.05 despite a 30-day rally of +59.2%, though the company posted a net loss of $69,234,000.00 over its most recent full fiscal year against revenue of $34,365,000.00, with annual revenue declining 16.7% year-over-year. His prior open-market sales across all tickers show a cross-ticker 90-day average return of +4.8%, while his prior Kymera sales on 2026-02-25 returned -10.0% and -10.6% over 90 days respectively. Because this transaction is scheduled under a 10b5-1 plan, it reflects a pre-set commitment rather than a discretionary timing decision.

CEO Mainolfi sold 30,000 shares at blended avg $81.18 on 2026-04-29; prior 5 KYMR sales all declined 12.9%–16.4% in 30 days

Mainolfi executed 3 separate sales totaling 30,000 shares for $2,435,377.20 at prices between $80.74 and $82.45, representing a -4.3% reduction in his holdings to 666.2K shares. The timing context is notable: his prior 5 trades at KYMR (all on 2026-02-25) showed consistent 30-day declines ranging from -12.9% to -16.4%, suggesting a pattern of selling into strength at this ticker. The current stock price of $81.51 sits -14.2% below its 52-week high of $95.03 and recently gained +2.6% (30-day). However, the company fundamentals present headwinds: annual revenue contracted -16.7% year-over-year, the latest quarter posted only $2.8M in revenue against a $-82.2M net loss, and the company remains unprofitable. The near-term sales follow established pattern: after similar-sized exits two months prior, equity holders absorbed double-digit declines. This sale occurs against weak operational performance and a documented pattern of subsequent stock weakness at this company.

CEO Mainolfi sells 30,000 shares for $2.7M at blended $90.26 as stock nears 52-week high of $94.30

Nello Mainolfi, Kymera's Chief Executive Officer, executed 5 separate sales totaling 30,000 shares for $2,707,812.59 on February 25, 2026, reducing his holdings by 4.3% to 666,195 shares. The transactions occurred at prices ranging from $89.78 to $93.49, with a blended average of $90.26—just 3.8% below the 52-week high of $94.30. This is noteworthy given Kymera's deteriorating fundamentals: the company reported annual revenue growth of -40.1%, a latest-quarter revenue of $2,764,000.00, and a net loss of $-82,175,000.00 for the fiscal year. At the same time, the stock has surged +27.6% over 30 days and +33.6% over 90 days, creating a tension between price momentum and operational results. His prior trades at KYMR show a mixed timing pattern: two December 2025 and one October 2025 sales have each posted negative 30-day returns (-7.4%, -6.8%, -14.0%), while two October 2025 sales posted positive returns, yet 0 of 2 measurable 90-day outcomes were well-timed (the stock rose after those sales). The current sale occurs near the peak of a strong rally into structurally weak fundamentals.

CEO Mainolfi sold 30,000 KYMR shares for $2.3M at $78.06 avg; holds 663.1K post-sale. Company posted -40.1% annual revenue decline.

Mainolfi executed 2 separate sales totaling 30,000 shares for $2,341,939.35, reducing his stake by 4.3%. The stock has risen 16.4% over the past 30 days and 39.0% over 90 days from trough, but remains 17.5% below its 52-week high of $94.30. Fundamentally, Kymera faces headwinds: annual revenue contracted 40.1% year-over-year to $2.8M in the latest quarter, and the company posted a $-82.2M net loss for its most recent full fiscal year. At the same ticker, Mainolfi's 5 prior trades show mixed timing: one measurable 90-day outcome (September 2025 sell) returned +74.9%, contradicting a well-timed pattern. The recent sales in December and late October occurred as the stock staged a rebound, offering no clear signal of foresight into either the near-term rally or the company's structural revenue decline.

CEO Mainolfi sold 100,000 shares at $89.17 for $8.9M; stock near 52-week high at $94.30 after +60.8% in 30 days.

CEO Nello Mainolfi sold 100.0K shares at $89.17, reducing holdings by 13.1% to 660.5K shares. The sale occurred at a price near the 52-week high of $94.30 (the filing records current price at $94.30, with the transaction at $89.17). The stock has surged +60.8% over the past 30 days and +116.9% over 90 days, placing the sale in a context of significant recent appreciation. At KYMR specifically, Mainolfi's prior four measurable sells all posted positive 30-day returns (+13.7%, +11.2%, +10.4%, +23.4%), with one of one prior sells at the 90-day mark showing a well-timed outcome (the June 2025 sale, which saw a -15.9% decline). The company faces fundamental headwinds: annual revenue contracted -40.1% year-over-year, the latest quarter posted only $2.8M in revenue against a -$82.2M net loss, and the enterprise remains unprofitable. This sale of a material block by the CEO follows an established pattern of regular dispositions at this ticker and occurs as the stock reaches elevated valuations.

CEO Mainolfi sells 30,000 KYMR shares (30.0K) for $1,829,736.92 in 3 transactions; holds 660.5K shares post-transaction.

Mainolfi executed 3 separate open-market sales totaling 30,000 shares for $1,829,736.92, reducing his holdings from 690.5K to 660.5K shares (-4.3%). The blended sale price of $60.99 sits 1.6% above the current price of $60.03, near the 52-week high of $62.89, against a backdrop of 37.2% gains over the past 90 days. At the same ticker, his prior sell on 2025-06-03 posted a -15.9% 90-day return (well-timed), but the company's fundamentals remain challenged: annual revenue contracted -40.1%, the latest quarter showed $11.5M revenue against a $-76.6M net loss, and the company has been unprofitable over its full fiscal year. The transaction occurs in a period of significant price appreciation, yet without visibility into his purchase history, settlement patterns, or personal liquidity needs, the sales alone do not establish a directional thesis about near-term stock performance.

CEO Nello Mainolfi sold 30,000 shares of KYMR at $49.00 on 2025-09-16; stock up 14.4% in 30 days but company posted -40.1% revenue decline.

Mainolfi sold 30,000 shares at $49.00, reducing his stake by 4.3% to 660,482 shares remaining. The sale occurred within a 14.4% 30-day rally and just 6.9% below the 52-week high of $52.40, suggesting the transaction executed during a period of upward momentum in the stock. His cross-ticker track record shows a 100.00% well-timed rate on prior sells, with the prior KYMR sale on 2025-06-03 also well-timed at the 90-day mark (both resulted in negative 90-day returns). However, the company's fundamentals present a sobering context: revenue contracted 40.1% year-over-year, the latest quarterly revenue stood at only $11.5M, and the company has sustained ongoing unprofitability with a -$76.6M net loss in the most recent period. The timing of this sale during a sharp rally, combined with the insider's demonstrated pattern of selling before subsequent declines at this exact ticker and the company's deteriorating financial trajectory, warrants investor scrutiny.

CEO Mainolfi sells 30,000 KYMR shares at $49.00; holds 660,482 post-sale as stock down 16.8% from 52-week high

Nello Mainolfi, Chief Executive Officer of Kymera Therapeutics, sold 30,000 shares at $49.00 on 2025-06-03, reducing his stake by -4.3% to 660,482 shares. The transaction occurred near the company's 52-week peak of $52.40, with the stock currently trading 16.8% below that high at $43.58. The context is material: Kymera reported Revenue $22,100,000.00 for the latest quarter against Net income $-65,581,000.00, with Annual revenue growth (FY vs prior FY) of -40.1%, reflecting significant operational headwinds. A CEO sale of material magnitude near cyclical peaks warrants investor attention, particularly given the company's sustained unprofitability and negative revenue trajectory.